Hiroaki Suga
Born
菅 裕明

(1963-02-21) February 21, 1963 (age 60)
Okayama, Japan
Education
Known forRNA-based catalysis
Awards
Scientific career
FieldsChemistry
Institutions
ThesisCatalytic antibodies elicited via homologous and heterologous immunization (1994)
Doctoral advisorSatoru Masamune [jp]

Hiroaki Suga (菅 裕明, born February 21, 1963) is a Japanese biochemist and businessman. He is best known for his work on artificial ribozymes (flexizymes) and their application in mRNA display (RaPID, random nonstandard peptide integrated discovery).[1][2]

Suga was awarded the 2023 Wolf Prize in Chemistry, jointly with Chuan He and Jeffery W. Kelly, "for pioneering discoveries that illuminate the functions and pathological dysfunctions of RNA and proteins and for creating strategies to harness the capabilities of these biopolymers in new ways to ameliorate human diseases."[1]

Education

Suga graduated from Okayama University (BSc, MSc) in engineering,[1][3] and studied at University of Lausanne, where he worked with Manfred Schlosser [de].[3]

Suga completed his Ph.D. in chemistry at Massachusetts Institute of Technology in 1994 with Satoru Masamune [jp],[3] working on catalytic antibodies[4]

Career

Scientific

After graduating from MIT with a Ph.D., Suga was a postdoctoral researcher at the Jack W. Szostak lab of Harvard Medical School before starting his independent career at University at Buffalo. Since 2003 he is a faculty member at the University of Tokyo.[3]

Business

Suga is also a founder of PeptiDream Inc. Tokyo, a publicly traded biopharmaceutical start-up company responsible for discovering and developing non-standard peptide therapeutics in addition to addressing unmet medical needs as well as investigating peptide drug conjugates (PDC), peptides, and small molecule-based drugs.[5][6][7] It is traded publicly on the Tokyo First Stock Exchange Market (the market capitalization is over JY 600 billions), which has many partnerships with pharmaceutical companies in worldwide.[2][8]

Suga is chair of the editorial board at RSC Chemical Biology[9] and associate editor at Angewandte Chemie.[2]

Publications

Suga has published over 250 scientific articles;[10] a small selection is presented here:

Awards

References

  1. ^ a b c d "Press release: Wolf Prize in Chemistry 2023" (Press release). Wolf Foundation. February 7, 2023.
  2. ^ a b c d e f "Press release: 2023 Wolf Prize in Chemistry Announced" (Press release). Chemistry Views. February 7, 2023.
  3. ^ a b c d "Hiroaki Suga, Ph.D. | Biographical Information". Retrieved February 11, 2023.
  4. ^ Suga, Hiroaki (1994). Catalytic antibodies elicited via homologous and heterologous immunization (Ph.D.). hdl:1721.1/17342.
  5. ^ "Prof. Dr. Hiroaki Suga: The pseudo-natural peptides therapeutic innovation". LMU München. December 10, 2018.
  6. ^ "Hiroaki Suga".
  7. ^ "Current Lecturer". November 11, 2022.
  8. ^ "Hiroaki Suga, Professor, University of Tokyo". Swiss National Center of Competence in Research. March 14, 2016.
  9. ^ "RSC Chemical Biology | About". Retrieved February 11, 2023.
  10. ^ "Suga Lab | Articles & Reviews". Retrieved February 11, 2023.
  11. ^ a b "Press release: UTokyo Professor Hiroaki Suga wins 2023 Wolf Prize in chemistry" (Press release). University of Tokyo. February 13, 2023.
  12. ^ "American Peptide Society | Vincent du Vigneaud Award". Retrieved February 11, 2023.
  13. ^ "Congratulations to Hiroaki Suga, awarded the Humboldt Research Award". Retrieved February 18, 2023.

External links

More
Scholia has a profile for Hiroaki Suga (Q11619370).
Laureates of the Wolf Prize in Chemistry
Authority control databases
Categories